Roche sales up 5 percent amid rush for Tamiflu, cancer drugs

Swiss drug giant Roche said Thursday that heightened demand for its Tamiflu drug amid a severe flu season, as well as for its cancer medicines had sent its first-quarter sales up five percent, beating analyst expectations.

During the first three months of the year, the company said its overall sales shot up to 11.6 billion Swiss francs ($12.4 billion, 9.5 billion euros).

Analysts polled by Swiss financial news agency AWP had expected it to rake in 11.4 billion francs during the period.

"We got off to a very good start in 2013 due to strong organic growth," Roche chief executive Severin Schwan said in a statement.

The growth was largely due to a spike in Tamiflu sales amid a difficult in the United States especially, as well as rising demand for its main cancer treatments, which helped push sales in the company's all-important Pharma division up 6.0 percent, to 9.1 billion Swiss francs.

Roche's Diagnostics division meanwhile saw more modest growth, with sales up just 1.0 percent from the same period in 2012 at 2.4 billion francs.

During the first quarter, Roche also launched two to fight , Kadcyla in the United States and Perjeta in Europe.

"Based on the first quarter results, I am confident we will meet our full-year targets," Schwan said, confirming Roche's forecast at the end of January that it will this year see sales rise at the same rate as in 2012, when they were up about 4.0 percent.

add to favorites email to friend print save as pdf

Related Stories

Cancer drugs give Roche a 2012 profit boost

Jan 30, 2013

Growing demand for its cancer medicines and diagnostic tests used by clinical laboratories helped Swiss drug maker Roche Holding AG post a modest 2.4 percent increase in full-year profits.

Roche profits drop on one-off costs

Jul 26, 2012

(AP) — One-off charges at Swiss drugmaker Roche Holding AG on Thursday pushed first-half net profits down 17 percent, but strong sales of cancer drugs and cost-cutting contributed to a rise in core operating ...

US approves Swiss firm's cervical cancer test

Apr 20, 2011

Swiss pharmaceutical giant Roche has been given the green light by US authorities to market its test for screening cervical cancer, the company announced on Wednesday.

Recommended for you

Added benefit of vedolizumab is not proven

19 hours ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments